๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes

โœ Scribed by Masahiko Tanabe; Yoshinori Ito; Nahomi Tokudome; Tsutomu Sugihara; Hiroyoshi Miura; Shunji Takahashi; Yasuyuki Seto; Takuji Iwase; Kiyohiko Hatake

Book ID
107643721
Publisher
Springer Japan
Year
2009
Tongue
English
Weight
174 KB
Volume
16
Category
Article
ISSN
1340-6868

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Combination chemotherapy for metastatic
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate
โœ Ambrose Aboud; Aman U. Buzdar; Hwee-Yong Yap; Gabriel N. Hortobagyi; George R. B ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 270 KB

Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue. Of 24 evaluable patients, one achieved a complete remission and 17 had partial responses. The overall objective response r

Mitomycin C, melphalan and methotrexate
Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer
โœ D. J. Perez; T. J. Powles; J. -C. Gazet; H. T. Ford; R. C. Coombes ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer ๐ŸŒ English โš– 299 KB

Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen. Of 48 evaluable patients 19 (40%) responded for a m